Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and Chief Commercial ...
StockStory.org on MSN
Bristol-Myers Squibb’s Q1 earnings call: Our top 5 analyst questions
Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady ...
Mirati Therapeutics, a San Diego biotechnology company developing commercial drugs for cancer treatment, was just purchased by a pharmaceutical giant for more than $4.8 billion. Bristol Myers Squibb, ...
Bristol-Myers Squibb has picked its new commercial chief—and the person who'll be charged with maximizing Opdivo's potential. Christopher Boerner, who's been running the company's international ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
INCHEON, South Korea, Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol ...
OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes Multi-year agreement with five-year initial term and option to extend Oxford, UK – 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results